J P Morgan Chase & Co Analysts Give AstraZeneca plc (AZN) a GBX 4,500 Price Target

AstraZeneca plc (LON:AZN) received a GBX 4,500 ($59.79) price target from analysts at J P Morgan Chase & Co in a research note issued on Wednesday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective suggests a potential downside of 12.89% from the company’s current price.

Other research analysts also recently issued reports about the stock. UBS AG set a GBX 5,150 ($68.43) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 27th. Credit Suisse Group cut their target price on shares of AstraZeneca plc from GBX 5,000 ($66.44) to GBX 4,700 ($62.45) and set a “neutral” rating on the stock in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.82) target price on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 2nd. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 2nd. Finally, HSBC Holdings plc downgraded shares of AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($59.79) target price on the stock. in a research report on Tuesday, July 4th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc currently has an average rating of “Hold” and a consensus target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON:AZN) opened at 5180.00 on Wednesday. The firm’s market cap is GBX 65.58 billion. The stock has a 50 day moving average of GBX 4,859.28 and a 200 day moving average of GBX 4,907.26. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Analysts Give AstraZeneca plc (AZN) a GBX 4,500 Price Target” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/18/j-p-morgan-chase-co-an

Other research analysts also recently issued reports about the stock. UBS AG set a GBX 5,150 ($68.43) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a research report on Tuesday, June 27th. Credit Suisse Group cut their target price on shares of AstraZeneca plc from GBX 5,000 ($66.44) to GBX 4,700 ($62.45) and set a “neutral” rating on the stock in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.82) target price on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 2nd. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, August 2nd. Finally, HSBC Holdings plc downgraded shares of AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($59.79) target price on the stock. in a research report on Tuesday, July 4th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc currently has an average rating of “Hold” and a consensus target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON:AZN) opened at 5180.00 on Wednesday. The firm’s market cap is GBX 65.58 billion. The stock has a 50 day moving average of GBX 4,859.28 and a 200 day moving average of GBX 4,907.26. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Analysts Give AstraZeneca plc (AZN) a GBX 4,500 Price Target” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/18/j-p-morgan-chase-co-analysts-give-astrazeneca-plc-azn-a-gbx-4500-price-target.html.

In related news, insider Nazneen Rahman acquired 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply